StrandTX

Menu

Hello worldHello world

News

Latest from the lab

Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting

Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer

Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer

Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Phase 1 dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients with advanced solid tumors

2025 ASCO Annual Meeting

Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting

Strand Therapeutics Reports Promising Start for mRNA Cancer Therapy

Long-acting circular RNA CAR drives potent and durable tumor elimination in vivo

STX-003: Cancer Immunotherapy with systemic delivery of mRNA utilizing programmable genetic circuits for precise regulation of IL-12 expression and reduced toxicity

Strand Therapeutics to Present Potential First-in-Class Data from Preclinical Program for STX-003, a Programmable mRNA Therapy to Treat Solid Tumor Cancers

STX-003: Utilizing Programmable Genetic Circuits for Tumor-Specific IL-12 Expression and Reduced Toxicity with Systemically Delivered mRNA

Synthetic Biology And Programmable mRNA With Strand Therapeutics' Jake Becraft

Strand Therapeutics Announces First Patient Dosed with Programmable mRNA Therapy STX-001 in Phase 1 Trial for Solid Tumors

Circular RNA Based Chimeric Antigen Receptor (CAR) Cell Therapy for Potent and Long-Lasting Anti-Tumor Activity

STX-003: A Novel Systemically-Delivered mRNA-Based Cancer Therapy Utilizing a Programmable Genetic Circuit Platform for Tumor-Specific Protein Expression and Reduced Toxicity

Unlocking mRNA’s Cancer-Fighting Potential

Scientists Will Test a Cancer-Hunting mRNA Treatment

Strand Therapeutics Receives IND Clearance for Programmable mRNA Therapy STX-001 to Treat Solid Tumors

Delivering on the Promise of Personalized mRNA Therapeutics

Genetic Engineering & Biotechnology News

The Next Generation of mRNA Beyond Vaccines with Strand Therapeutics

100 Fastest Growing Companies in Boston 2023: Top Startups

Strand Therapeutics Appoints Colleen Wilson as Chief People Officer

Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023

Strand Therapeutics Announces Poster Presentation on STX-001 at the 2023 AACR Annual Meeting

RNA Therapies Diversify and Become More Impactful

Genetic Engineering & Biotechnology News

RNA Companies to Watch Over the Next 12 Months

Beyond vaccines: Where mRNA technology goes next

Defining The RNA Therapeutics Industry In 2023

Bioprocess Online

mRNA & RNA Therapeutics In 2023: Where Do We Go From Here?

Boston mRNA Startup Raises Millions to Test its Targeted Cancer Therapies

The Boston Globe

Lilly backs $45M investment for mRNA cancer immunotherapy startup

Boston Business Journal

Strand Therapeutics raises additional capital to series A financing

Chemical & Engineering News

mRNA startup Strand Therapeutics raises millions to test targeted cancer therapies

Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million

Covid-19 vaccines were a success, but mRNA still has a delivery problem. Two startups have an unorthodox solution

Duke, MIT, Stanford Scientists Create RNA Technology That Could Improve Genetic Therapies

The Boston Globe

A longtime believer in mRNA, Strand Therapeutics’ co-founder is now pushing the tech to the next level

Fierce Biotech's 2022 Fierce 15

Fierce Biotech names Strand Therapeutics as one of its “Fierce 15” Biotech Companies of 2022

Meet the 30 young leaders forging a new future for the healthcare industry in 2022

Business Insider

Cancer biotech exec blends biotech, philosophy, entrepreneurship

Boston Business Journal

Cancer Therapeutics Target the Undruggable, Confront Other Bugbears

Genetic Engineering & Biotechnology News

The 20(+1) under 40: Your guide to the next generation of biotech leaders

Nucleic Acid-based Therapeutics Are Stepping into the Spotlight

BioPharm International

Strand Therapeutics Appoints Dr. Prashant Nambiar as Senior Vice President, Research and Translational Development

Messenger RNA Took on Covid-19. This Startup Says That’s Just the Beginning

Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancer

MIT Tech Review – 35 Innovators Under 35

MIT Technology Review

Strand Therapeutics’ Jake Becraft Named an MIT Technology Review 2021 Innovator Under 35

This Synthetic Bio Startup Raised $52 Million To Make Tumors Reveal Themselves

Strand snags $52M to develop next-gen mRNA meds for cancer

Strand Therapeutics Raises $52M in Oversubscribed Series A Round

10 Breakthrough Technologies 2021

MIT Technology Review

Strand CEO Jake Becraft on Squawk Box Asia talks mRNA Vaccines and BeiGene licensing deal.

Strand Therapeutics

Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology

Pseudovirus for immunotherapy

Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity

Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery

Small-molecule-based regulation of RNA-delivered circuits in mammalian cells

Nature Chemical Biology